2015 top banner
 

c-MET Antibodies


c-MET Pathway Antibodies and Reagents


Humans have 58 known receptor tyrosine kinases (RTKs) which fall into 20 subfamilies. c-MET and RON are two receptor tyrosine kinases that belongs to the c-MET proto-oncogene family. c-Met and RON share similar structural and biochemical properties. Both proteins are heterodimers composed of a ~40Kda extracellular a-chain and a ~150 kDa transmembrane b-chain with intrinsic tyrosine kinase activity. c-Met is a receptor for hepatocyte growth factor (HGF), while RON is recognized by macrophage-stimulating protein (MSP), also known as HGF-like protein. c-Met and RON both are expressed by a variety of epithelial-derived tumors and cancer cell lines and thought to play a functional role in tumorigenesis and invasive-metastatic phenotypes.  Both RON and c-Met are recent targets of drug studies to control cell migration and matrix invasion.

Rockland Immunochemicals has developed a suite of research antibodies targeting activated and inactivated critical components of the c-MET signal pathway. These antibodies are designed to detect the phosphorylated and dephosphorylated forms of c-MET and RON, and their downstream adapter GAB1.  

  


 

Featured Antibodies Targeting c-MET Pathway


cmet1
 

 

cmet2
 

 

cmet3
 

c-MET detection by Western blot using affinity purified
pY1349pY1356 anti-c-Met antibody.
The picture shows that phosphorylated c-Met is detected only in HGF-stimulated cells.

 

Detection of Gab1 using
anti-GAB1 antibody in the
absence and presence of
competing Gab1 peptide.

 

Detection of active RON pY1360
protein fragment using
anti-RONpY1360 antibody in the absence and presence of competing RONpY1360 peptide

         

 

Suggested Products for Common Assays

 

For detection of total RON protein, pan-reactive rabbit polyclonal antibodies that have been raised against RON recombinant protein or rabbit polyclonal antibodies raised against peptide epitopes (RON against residues surrounding Y1360 and RON against residues surrounding Y1353 of human RON protein) is recommended.  

To detect various phosphorylated c-MET or RON or Gab1  isoforms, respective phospho-specific and site-specific antibodies are recommended. For example, RON phosphorylated at Y1353  position can be detected using  phospho-specific RON pY1353 Antibody. For RON phosphorylated at Y1360 position, the  phospho-specific RON pY1360 Antibody should be used. Similarly, to detect phosphorylation of c-MET at Y1349/Y1356 or Gab1 at Y659, c-Met phospho Y1349 / Y1356 Antibody or  GAB1 pY659 Antibody should be used.

 



 

Featured c-MET Primary Antibodies

 

Product Name

Catalog

Application

Size

c-Met phospho Y1349/Y1356 Antibody (Rabbit)

600-401-989

ELISA, WB 

100 µg

RON Antibody  (Rabbit)

200-401-G67

ELISA, WB 

100 µg

RON Antibody  (Rabbit)

600-401-K07

ELISA, WB 

100 µg

RON phospho pY1360 Antibody (Rabbit)

600-401-G70

ELISA, WB 

100 µg

RON phospho pY1353 Antibody (Rabbit)

600-401-G69

ELISA, WB 

100 µg

Anti-GAB1 Antibody

600-401-K05

ELISA, WB 

100 µg

Anti-GAB1 Antibody

200-401-G66

ELISA, WB 

100 µg

GAB1 phospho  pY659 Antibody (Rabbit)

600-401-G68

ELISA, WB 

100 µg

 

c-MET Pathway Antibodies and Reagents

Abstract
Rockland  have developed a suite of reagents to detect phosphorylated and inactive forms of c-MET and RON as well as their downstream adapter GAB1. These reagents are applicable for profiling c-MET pathway proteins  and their phosphorylated stages in human cells for monitoring the efficacy of anti-cancer drugs. 

Applications
Reagents  for  c-MET pathway  pharmacodynamic study.

Advantages
c-Met and RON both are expressed by a variety of epithelial-derived tumors and cancer cell lines and thought to play a functional role in tumorigenesis,  invasive-metastatic phenotypes. Both RON and c-Met have become a drug target to control cell migration and matrix invasion.  Developed antibodies enables to rapidly quantify c-MET family proteins and their phosphorylated stages in cells upon exposure to anticancer drugs, thereby allowing preclinical evaluation the anti-cancer drug efficacy and potential resistance problems. 
  

To discuss licensing or custom services opportunities please contact:

Dan Kenney
Director, Scientific Business Development
(484) 791-3823

 

 Contact Us

 

Phospho Antibodies


The TrueBlot® Concept Map outlines the major mechanisms by which TrueBlot® can create exceptionally clear results.

 

TrueBlot IP Western Blot Technology


Read more about TrueBlot® Publication-quality IP western blot data.